Loading...
AnGes, Inc.
AMGXF•PNK
Healthcare
Biotechnology
$0.36
$0.00(0.00%)
AnGes, Inc. (AMGXF) Financial Performance & Income Statement Overview
Review AnGes, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
320.30%
↑ 320.30%
Operating Income Growth
23.88%
↑ 23.88%
Net Income Growth
-278.20%
↓ 278.20%
Operating Cash Flow Growth
24.38%
↑ 24.38%
Operating Margin
-1977.25%
↓ 1977.25%
Gross Margin
-369.17%
↓ 369.17%
Net Profit Margin
-1543.06%
↓ 1543.06%
ROE
-24.04%
↓ 24.04%
ROIC
-30.56%
↓ 30.56%
AnGes, Inc. (AMGXF) Income Statement & Financial Overview
Review AnGes, Inc.'s (AMGXF) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $172.00M | $124.00M | $234.01M | $113.56M |
| Cost of Revenue | $111.00M | $85.00M | $158.00M | $855.84M |
| Gross Profit | $61.00M | $39.00M | $76.01M | -$742.28M |
| Gross Profit Ratio | $0.35 | $0.31 | $0.32 | -$6.54 |
| R&D Expenses | $855.00M | $683.00M | $1.27B | $971.54M |
| SG&A Expenses | $1.27B | $1.29B | $1.43B | $762.87M |
| Operating Expenses | $2.13B | $1.97B | $2.71B | $1.73B |
| Total Costs & Expenses | $2.24B | $2.06B | $2.87B | $2.59B |
| Interest Income | $1.52M | $0.00 | $663000.00 | $1.79M |
| Interest Expense | -$478000.00 | $0.00 | $25.44M | $4.92M |
| Depreciation & Amortization | $842.50M | $777.00M | $876.92M | $815.22M |
| EBITDA | -$1.23B | -$1.16B | -$1.79B | -$1.70B |
| EBITDA Ratio | -$7.13 | -$9.33 | -$7.63 | -$14.97 |
| Operating Income | -$2.07B | -$1.94B | -$2.63B | -$2.48B |
| Operating Income Ratio | -$12.02 | -$15.60 | -$11.24 | -$21.81 |
| Other Income/Expenses (Net) | -$18.51B | -$1.71B | $984.37M | $705.58M |
| Income Before Tax | -$20.58B | -$3.65B | -$1.65B | -$1.77B |
| Income Before Tax Ratio | -$119.64 | -$29.41 | -$7.04 | -$15.60 |
| Income Tax Expense | $394.00M | $9.00M | $29.52M | $52.94M |
| Net Income | -$20.97B | -$3.66B | -$1.68B | -$1.82B |
| Net Income Ratio | -$121.93 | -$29.48 | -$7.16 | -$16.06 |
| EPS | -$75.80 | -$15.06 | -$7.54 | -$9.14 |
| Diluted EPS | -$75.80 | -$15.06 | -$7.54 | -$9.14 |
| Weighted Avg Shares Outstanding | $276.67M | $242.79M | $222.29M | $199.56M |
| Weighted Avg Shares Outstanding (Diluted) | $276.67M | $242.79M | $222.29M | $199.56M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan